Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Commentary Author: Orly Avitzur, Consumer Reports Medical Adviser Last Updated: Oct 29, 2009 - 3:26:19 PM



Smart Pills: More Focus or Hocus Pocus?

By Orly Avitzur, Consumer Reports Medical Adviser
Oct 29, 2009 - 3:22:29 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - They’re all the buzz, and more of my patients seem to be asking for them: Drugs that can improve attention span and memory and help them be more productive at work. That may explain why the demand for neuroenhancement medication seems to be gaining steam. Prescriptions for the 18-year-old-and-older age group have been steadily rising, with 3.2 million recorded between November 2006 and October 2007. In one survey conducted in 2008 by the scientific journal Nature, 20 percent of respondents admitted to using neurocognitive-enhancing drugs, mostly to improve concentration.

Examples include stimulants such as Ritalin (methylphenidate) and Adderall (amphetamine/dextroamphetamine combination)—the drugs used for children with attention deficit hyperactivity disorder (ADHD)—to improve performance on academic tests and to learn new skills, and cholinesterase inhibitors like Aricept (donepezil), the Alzheimer’s medication, to treat normal age-related memory changes. They also include Provigil (modafinil), the drug used off-label to keep pilots alert and approved to treat narcolepsy and sleep apnea.

Some say that they’re better than a double-espresso, but do they work? According to new guidance by the American Academy of Neurology (AAN):

"Medications currently used for neuroenhancement do not appear to act uniformly to improve executive function or memory across age groups (e.g. elderly/young), populations (high/low IQ), or tasks (novel/repetitive), and in some cases may make cognitive function worse. Thus, the idea of simply "making people smarter" by prescribing these medications ignores the complex nature of cognitive function. In addition, the risks of the long-term use of off-label medications for neuroenhancement in normal patients without a medical or mental health condition are not known and may not be known for many years." The AAN statement goes on to advise neurologists like me to exercise our clinical and ethical judgment to decide whether to prescribe medications for neuroenhancement. But proponents argue that if we don’t get on the bandwagon, we’ll be at a competitive disadvantage, not only as individuals but as a nation in this global economy.

Without data on the long-term side effects, are you tempted to take the risk?

Photo courtesy of hipsxxhearts

Subscribe to our FREE Ezine and be eligible for Health News, discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
We videotape Press Conferences, produce SMT's, VNR's, B-rolls, PSA's, - all with distribution: HealthyTelevisionProductions

Top of Page

HealthNewsDigest.com

Commentary
Latest Headlines


+ Public Service Announcements (PSAs) as an Effective Marketing Tool
+ Federation of American Hospitals Commends House Passage of Health Reform
+ Smart Pills: More Focus or Hocus Pocus?
+ Watching My Mother Die of Breast Cancer
+ Medicare’s Missing Link: Care Coordination and Family Caregiving
+ Stanford Bioethicist Discusses Ethical Myths Surrounding Health-Care Reform
+ AMA Affirms Support for Health Reform
+ William H. Meadows, President of The Wilderness Society on Passage of the American Clean Energy and Security Act
+ Chronic Fatigue Syndrome Awareness Day
+ AMA Commits to Help Slow Increases in Health Spending



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions